Effect of Methyldopa on Uterine Artery Diameter in Pregnant Women With Mild Preeclampsia
|ClinicalTrials.gov Identifier: NCT01674127|
Recruitment Status : Completed
First Posted : August 28, 2012
Last Update Posted : August 28, 2012
|Condition or disease||Intervention/treatment||Phase|
|Pregnant Women With Mild Preeclampsia||Drug: Methyldopa Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Study Start Date :||August 2011|
|Actual Primary Completion Date :||February 2012|
|Actual Study Completion Date :||May 2012|
In case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days.
|Placebo Comparator: placebo||
- Doppler indices [ Time Frame: 7 days ]
In case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days.Before and after drug use, Doppler ultrasound test was done by a radiology specialist not informed of patients grouping. Also, pulsatility index, resistance index, systolic/diastolic blood flow ratios of uterine artery, umbilical artery and middle-cerebral artery were evaluated. Registered for all patients, age, BMI, gestational week and the number of pregnancies were among other examined variables.
Doppler indices of examined arteries in studied groups were evaluated by color Doppler ultrasound of model "Hitachi 3/6 MHz".